Search

Displaying results 5081 - 5090 of 10000 in total
  1. Drug

    Dexchlorpheniramine

    go.drugbank.com/drugs/DB13679
    Investigational

    It is an antihistamine drug with anticholinergic (drying) and sedative actions. It disrupts histamine signaling by competing with histamine for cell receptor sites on effector cells.

  2. Drug

    Ciglitazone

    go.drugbank.com/drugs/DB09201
    Experimental

    Ciglitazone is a potent and selective PPARγ ligand with an EC50 of 3.0 µM. It is also an anti-hyperglycemic agent in the ob/ob murine model in vivo. … Ciglitazone significantly decreases VEGF production by human granulosa cells in an in vitro study, and may potentially be used in ovarian hyperstimulation syndrome.

  3. Drug

    Pozanicline

    go.drugbank.com/drugs/DB05458
    Investigational

    In radioligand binding studies, ABT-089 has shown selectivity toward the alpha4beta2 nAChR subtype as compared to the alpha7 and alpha1beta1deltagamma nAChR subtypes.

  4. Drug

    LErafAON

    go.drugbank.com/drugs/DB04973
    Investigational

    Phase I/II trials commenced in March 2001 and were ongoing as of June 2003.

  5. Drug

    Dihydrotachysterol

    go.drugbank.com/drugs/DB01070
    ApprovedWithdrawn

    A vitamin D that can be regarded as a reduction product of vitamin D2.

  6. Drug

    Bezitramide

    go.drugbank.com/drugs/DB01459
    ApprovedIllicitWithdrawn

    After cases of fatal overdose in the Netherlands in 2004 the drug was withdrawn from the market. Bezitramide has never been FDA approved and is currently a schedule II drug. … Bezitramide is a narcotic analgesic which was discovered in 1961, clinically tested around the 1970's [A14383], and marketed under the name Burgodin.

  7. Drug

    Pemoline

    go.drugbank.com/drugs/DB01230
    ApprovedIllicitWithdrawn

    In 2005, the Food and Drug Administration (FDA) withdrew approval for pemoline. In March 2005, Abbott Laboratories (Cylert marketer) had discontinued the production of Cylert arguing economic reasons.

  8. Drug

    Methapyrilene

    go.drugbank.com/drugs/DB04819
    ApprovedWithdrawn

    Methapyrilene, formerly marketed in many drug products, was shown to be a potent carcinogen. Manufacturers voluntarily withdrew methapyriline drug products from the market in May and June 1979.

    Synonyms: N-(α-pyridyl)-N-(α-thenyl)-N',N'-dimethylethylenediamine, N,N-dimethyl-N'-pyrid-2-yl-N'-2-thenylethylenediamine
  9. Drug

    Parsaclisib

    go.drugbank.com/drugs/DB14867
    Investigational

    Parsaclisib is under investigation in clinical trial NCT03126019 (An Open-Label Study of Parsaclisib in Relapsed or Refractory Follicular Lymphoma (CITADEL-203)).

  10. Drug

    Narazaciclib

    go.drugbank.com/drugs/DB19038
    Investigational

    Narazaciclib is under investigation in clinical trial NCT06351644 (On 123300 (Narazaciclib) and Dexamethasone in Patients With Relapsed And/or Refractory Multiple Myeloma).